Fragmentomics features of ovarian cancer

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Ovarian cancer (OC) is a leading cause of cancer mortality in women globally.
• Early diagnosis is challenging due to occult onset, nonspecific symptoms, and limited effective tools, leading to advanced-stage detection.
• Current diagnostic methods like CA125 and ROMA index have limitations in sensitivity and specificity.

Purpose of the Study:

• To investigate the utility of circulating tumor DNA (ctDNA) fragmentomics for ovarian cancer diagnosis.
• To develop and validate a machine learning model for identifying OC based on ctDNA fragment patterns.
• To compare the diagnostic performance of fragmentomics with established serum biomarkers.

Main Methods:

• Shallow whole-genome sequencing was employed to analyze ctDNA fragmentomics profiles.
• A machine learning model was developed to classify OC patients based on fragmentomics data.
• Comparative analysis was conducted against cancer antigen 125 (CA125) and Risk of Ovarian Malignancy Algorithm (ROMA) index.

Main Results:

• The machine learning model achieved a high diagnostic accuracy, with a mean area under the curve (AUC) of 0.97.
• Fragmentomics-derived OC scores demonstrated a strong correlation with disease stage.
• The fragmentomics-based approach showed superior clinical utility compared to CA125 and ROMA index.

Conclusions:

• Fragmentomics features in ctDNA represent a promising novel biomarker for accurate ovarian cancer diagnosis.
• This technology offers potential for earlier and more precise detection of OC.
• ctDNA fragmentomics provides significant clinical advantages over current diagnostic standards.